Shots:

• The companies collaborated to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PT199 in the P-I study in combination with BeiGene's tislelizumab for multiple advanced solid tumors that have progressed after all available standard therapy
• Through the activation of Ab-dependent macrophage-mediated killing of T effector cells, binding to Fc receptors on macrophages has been demonstrated in pre-clinical studies of tislelizumab to compromise the anti-tumor activity of PD-1 Ab
• PT199 is an anti-CD73 mAb that inhibits the enzyme activities of both soluble and membrane-bound CD73. Tislelizumab is being studied in solid tumors and hematologic malignancies as monotx. and in combination

Ref: PRNewswire | Image: BeiGene